Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages

Immunity and Inflammation in Atherosclerosis

(2019) Dennis Wolf et al.   CIRCULATION RESEARCH

The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors

(2019) Recep Bayraktar et al.   Frontiers in Immunology

Macrophage polarization in atherosclerosis

(2019) Sai Yang et al.   CLINICA CHIMICA ACTA

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice

(2019) Jan Pennig et al.   Scientific Reports

KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway

(2019) Xiaopei Liu et al.   CELLULAR SIGNALLING

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

(2018) Chenke Xu et al.   BIOCHEMICAL PHARMACOLOGY

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

(2018) Dustin M. Lee et al.   Cardiovascular Diabetology

Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect

(2018) Samy Suissa   DIABETES CARE

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease

(2018) Fabrice Bonnet et al.   DIABETES & METABOLISM

A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition

(2018) Yasutaka Miyachi et al.   Scientific Reports

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

(2018) Laween Uthman et al.   Frontiers in Physiology

New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis

(2018) Ting Yuan et al.   Redox Biology

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

(2017) Tsung-Ming Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

Schisandrin B inhibits LPS-induced inflammatory response in human umbilical vein endothelial cells by activating Nrf2

(2017) Qiuning Lin et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

(2017) Yusuke Nakatsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

(2017) Piangkwan Sa-nguanmoo et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

(2016) Muhammad Abdul-Ghani et al.   DIABETES CARE

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

(2016) Ji Hye Han et al.   DIABETOLOGIA

miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-κB and TNFαto Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose

(2016) Eun-Ah Ye et al.   MEDIATORS OF INFLAMMATION

MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA

(2016) Dan Li et al.   MOLECULAR IMMUNOLOGY

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

(2016) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes

(2016) Sivaram Pillarisetti   TRENDS IN PHARMACOLOGICAL SCIENCES

Apolipoprotein E Enhances MicroRNA-146a in Monocytes and Macrophages to Suppress Nuclear Factor- B-Driven Inflammation and Atherosclerosis

(2015) K. Li et al.   CIRCULATION RESEARCH

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting inflammation in the treatment of type 2 diabetes: time to start

(2014) Marc Y. Donath   NATURE REVIEWS DRUG DISCOVERY

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

(2014) Sophia Zoungas et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression

(2014) Michael Peled et al.   Frontiers in Immunology

Enhancement of lipopolysaccharide-induced toll-like receptor 2 expression and inflammatory cytokine secretion in HUVECs under high glucose conditions

(2013) Ying-ying Chen et al.   LIFE SCIENCES

Toll like receptor signaling in “inflammaging”: microRNA as new players

(2013) Fabiola Olivieri et al.   Immunity & Ageing

Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155

(2012) Xing Cai et al.   Journal of Molecular Cell Biology

Endocrine disrupting chemicals and disease susceptibility

(2011) Thaddeus T. Schug et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications

(2010) Corey E. Tabit et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE